产品封面图

Dofequidar

收藏
  • ¥600
  • 上海莼试
  • CS-01Y74630
  • 国产
  • 2025年07月08日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 技术资料
    • 库存

      21

    • 英文名

      Dofequidar

    • CAS号

      129716-58-1

    • 供应商

      上海莼试

    • 保存条件

      Store at -20°C

    • 规格

      5mg 10mg 50mg 100mg

    产品描述:
    分子式:C30H31N3O3

    产品细节图片1
    分子量:481.59
    溶解度:Soluble in DMSO
    储存条件:Store at -20°C
    General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the   ultrasonic bath for a while.
    Shipping Condition:Evaluation sample solution : ship with blue ice All other available size: ship with RT , or   blue ice upon request                                      
    Dofequidar(MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR.IC50 value: Target: P-gpin vitro: MS-209 at 3 microM effectively overcame docetaxel resistance in MDR cancer cells, and this concentration was achieved in blood plasma for > 7 h without serious toxicity [1]. MS-209 restored chemosensitivity of SBC-3 / ADM cells to VP-16, ADM, and VCR in a dose-dependent manner in vitro [2]. MS-209 strongly reversed drug resistance to adriamycin (ADM) and vincristine (VCR) in acquired MDR tumor cell lines, 2780AD and KB-C1. In addition, MS-209 enhanced the cytotoxic effect of ADM and VCR on various human and murine cell lines. Particularly in 4-1St cells, which are extremely resistant to ADM and VCR, MS-209 at a concentration of 3 microM enhanced the cytotoxicity of ADM and VCR, 88- and 350-fold, respectively [3].in vivo: Treatment with docetaxel alone at the maximal tolerated dose (MTD) showed an apparent antitumor activity to an intrinsically resistant HCT-15 tumor xenograft, and MS-209 additionally potentiated the antitumor activity of docetaxel. Against a MCF-7/ADM tumor xenograft expressing larger amounts of P-gp, docetaxel alone at the MTD showed no antitumor activity, whereas the MTD of docetaxel combined with MS-209 greatly reduced MCF-7/ADM tumor growth [1]. Intravenous injection with SBC-3 or SBC-3 / ADM cells produced metastatic colonies in the liver, kidneys and lymph nodes in natural killer (NK) cell-depleted severe combined immunodeficiency (SCID) mice, though SBC-3 / ADM cells more rapidly produced metastases than did SBC-3 cells. Treatment with VP-16 and ADM reduced metastasis formation by SBC-3 cells, whereas the same treatment did not affect metastasis by SBC-3 / ADM cells. Although MS-209 alone had no effect on metastasis by SBC-3 or SBC-3 / ADM cells, combined use of MS-209 with VP-16 or ADM resulted in marked inhibition of metastasis formation by SBC-3 / ADM cells to multiple organs [2]. MS-209 administered orally, together with ADM, enhanced the antitumor activity of ADM on Colon 26 and 4-1St tumors implanted subcutaneously (SC) in mice; the antitumor effect of ADM plus MS-209 was higher than that of ADM alone at the maximum tolerated dose (MTD) [3].
    商品属性:
    货号CS-01Y74630规格5mg 10mg 50mg 100mg
    CAS号129716-58-1分子量481.59
    含量>98.00%别名N/A
    分子式C30H31N3O3化学名N/A
    产地国产用途仅供科研研究实验
    注意事项:
    抗逆滴加序列
    每次向板内滴加抗原时,移液器滴头要与平面45度悬空,不要触碰到孔内的液体,由后向前依次滴加(即浓度由低往高滴加)。
    抗感染反应期
    抗原抗体在室温20~25℃下,必须反应30min以上,若环境温度低于室温,可将微量反应板置于恒温培养箱中,使二者充分反应。
    旅游温度
    磷酸盐缓冲液的pH值要在高压灭菌后进行滴定,往往在高压后pH值会有所改变,所以高压后再调一次pH值更为准确。磷酸盐缓冲液一经使用保存期不要超过3周。当pH<5.8时,红细胞会产生自凝现象;当pH>7.8时,图形洗脱加快,易造成肉眼观察产生误差;p H=7.2时,红细胞沉降最充分,图形最清晰。
    当滴注 1%红细胞悬液时,应经常摇晃红细胞悬液,使红细胞均匀地分布在磷酸缓冲液中,以防止红细胞下降。
    反应时间及温度
    加入鸡红血球之后,反应板在室温(20~25℃)静置30~40min,对照孔血球下沉于孔底,即可判定结果。若室温达不到实验要求,需相应调整反应时间。当环境温度低于4℃时,红细胞发生自凝;高于37℃时,会发生反应物分离和红细胞溶血。
    公司正在出售的产品:
    Recombnant Moue glech proten,C-Fc TagNDST2 Antibody Blocking Peptide
    Recombinant Human RAB13Recombinant Human Kallikrein 8 protein ,C- His Tag
    GBP1 Antibody Blocking PeptideRecombinant Human BCL2L2, N-His
    THBD Antibody Blocking PeptideRecombinant Blood fluke GST 26 protein ,GST Tag
    SF3B3 Antibody Blocking PeptideRecombinant Human CTRB2, N-GST
    NUS1 Antibody Blocking PeptideRecombinant Human MIF, C-His
    EPHA1 Antibody Blocking PeptideRecombinant Human MYO1A, N-His
    CDH5 Antibody Blocking PeptideRho GTP酶激活蛋白13封闭多肽
    SLIT1 Antibody Blocking PeptideRecombinant Human DEFa1 protein
    Recombinant SARS-CoV-2 (Omicron, B.1.1.529/BA.2 ) Spike RBD Protein (G339D、 S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H)Recombinant Human CC2D1A, N-His
    MAPK14 Antibody Blocking PeptideRecombinant Human CD150/SLAMF1, N-His
    EPB41L5 Antibody Blocking PeptideRecombinant Chicken  P01005 protein,N-His  Tag
    PDGFRB Antibody Blocking PeptideDofequidarRecombinant Mouse Relt protein ,C- His Tag
    P-selectin Antibody Blocking PeptideRecombinant Lujo mammarena Glycoprotein protein , N-His tag
    MOCS1 Antibody Blocking PeptideRecombinant Human NRG1 protein ,N- His Tag
    使用方法:
    1.本蛋白酶抑制剂混合物为100×的储存液,使用时按照1:100的比例加入到裂解液中(例如,1ml裂解液中加入10μl蛋白酶抑制剂混合物),混匀后即可使用。根据需要,0.5M的EDTA也按照1:100的比例加入到裂解液中(如用于检测金属蛋白酶活性,则不宜添加EDTA)。含有蛋白酶抑制剂混合物的裂解液宜现用现配,不宜配制后冻存待后续使用。
    2. 待所需的抑制剂添加完毕混匀后,就可以开始进行哺乳动物组织的裂解和蛋白提取。


     

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥33
    艾美捷科技有限公司
    2025年07月15日询价
    询价
    北京盛科博源生物科技有限公司
    2025年05月19日询价
    ¥602
    博奥派克生物
    2023年10月19日询价
    ¥100
    无锡天萃生物科技有限公司
    2025年12月12日询价
    ¥8302
    上海吉至生化科技有限公司
    2025年06月30日询价
    Dofequidar
    ¥600